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Abstract
Background: Human Immunodeficiency virus type-1 (HIV) entry into target cells involves binding of the viral envelope (Env)
to CD4 and a coreceptor, mainly CCR5 or CXCR4. The only currently licensed HIV entry inhibitor, maraviroc, targets CCR5,
and the presence of CXCX4-using strains must be excluded prior to treatment. Co-receptor usage can be assessed by
phenotypic assays or through genotypic prediction. Here we compared the performance of a phenotypic Env-Recombinant
Viral Assay (RVA) to the two most widely used genotypic prediction algorithms, Geno2Pheno[coreceptor] and webPSSM.
Methods: Co-receptor tropism of samples from 73 subtype B and 219 non-B infections was measured phenotypically using
a luciferase-tagged, NL4-3-based, RVA targeting Env. In parallel, tropism was inferred genotypically from the corresponding
V3-loop sequences using Geno2Pheno[coreceptor] (5–20% FPR) and webPSSM-R5X4. For discordant samples, phenotypic
outcome was retested using co-receptor antagonists or the validated TrofileH Enhanced-Sensitivity-Tropism-Assay.
Results: The lower detection limit of the RVA was 2.5% and 5% for X4 and R5 minority variants respectively. A phenotype/
genotype result was obtained for 210 samples. Overall, concordance of phenotypic results with Geno2Pheno[coreceptor] was
85.2% and concordance with webPSSM was 79.5%. For subtype B, concordance with Geno2pheno[coreceptor] was 94.4% and
concordance with webPSSM was 79.6%. High concordance of genotypic tools with phenotypic outcome was seen for
subtype C (90% for both tools). Main discordances involved CRF01_AE and CRF02_AG for both algorithms (CRF01_AE: 35.9%
discordances with Geno2Pheno[coreceptor] and 28.2% with webPSSM; CRF02_AG: 20.7% for both algorithms). Genotypic
prediction overestimated CXCR4-usage for both CRFs. For webPSSM, 40% discordance was observed for subtype A.
Conclusions: Phenotypic assays remain the most accurate for most non-B subtypes and new subtype-specific rules should
be developed for non-B subtypes, as research studies more and more draw conclusions from genotypically-inferred tropism,
and to avoid unnecessarily precluding patients with limited treatment options from receiving maraviroc or other entry
inhibitors.
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Introduction
Entry of the Human Immunodeficiency Virus type 1 (HIV-1)
into target cells is a three-step process involving sequential
interactions between the viral envelope glycoprotein trimer (Env)
with the CD4 receptor and one of two coreceptors, CCR5 or
CXCR4 [1–7]. Binding to the CD4 receptor induces a series of
conformational changes within Env that expose the third
hypervariable region (V3-loop), which in turn binds the corecep-
tor, ultimately leading to the so-called ‘‘fusion-active’’ state
required for fusion of the viral and cellular membranes [8]. The
V3-loop, which is the main determinant of coreceptor binding,
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therefore largely accounts for viral tropism [9,10], and viral strains
are classified as R5, when using the CCR5 coreceptor for viral
entry, X4 when using CXCR4, and dual-tropic or mixed (R5X4)
when using both coreceptors [11]. Other regions of Env, and
namely the V1/V2 loops and the constant region C4, have been
shown to also participate in viral tropism [12,13].
R5 strains are generally predominant during the early stages of
infection and are thought to be preferentially transmitted by
distinct, not yet fully elucidated processes [14,15]. As infection
progresses, viral strains feature increased variability within the
infected host, and particularly, Envs acquire broadened coreceptor
usage. At late stages of infection, X4 strains become dominant in
50% of patients infected with subtype B strains [16], but subtype-
related specificities have been reported [17–20]. X4 strains
replicate more rapidly than R5 strains in vitro and have been
associated with increased cytopathicity. In vivo, the appearance of
X4 strains correlates with a sharp decline of CD4+ T cells and the
onset of AIDS defining symptoms [21].
With the advent of entry inhibitors targeting CCR5, such as
maraviroc, monitoring coreceptor usage has become prerequisite
to the prescription of such entry inhibitors, in order to exclude the
presence of X4 or R5/X4 variants [22–24]. Under maraviroc
selective pressure, pre-existing X4 or DM strains can be selected.
CCR5 is a cellular target and resistance to maraviroc most often
arises through the re-emergence of archived minority X4 strains
rather than through a coreceptor usage switch or through the
acquisition of mutations that allow gp120 to engage with drug-
bound CCR5 [25–28]. Viral coreceptor usage can be measured
in vitro by phenotypic and genotypic assays [29]. Various
phenotypic assays based on different techniques are currently
available, including the TrofileH Enhanced-Sensitivity-Trofile-
Assay (ESTA) (Monogram Biosciences, South San Francisco,
CA) [30], the Virco phenotypic test (Virco BVBA, Mechelen,
Belgium) and others [30–33], which are based on pseudovirions,
and assays based on recombinant viruses, among which are the
Phenoscript test (VIRalliance, France) [34] and the Toulouse
Tropism Test [35]. These assays, their design and performance
are summarized in Table 1. The Trofile assay is the most widely
used in the clinic. It features a high sensitivity in detecting X4
minority variants [30]. Nonetheless, because phenotypic tests are
expensive, time consuming and require specialized laboratories,
more interest has been driven toward genotypic testing. Genotypic
assays are based on predictions of coreceptor usage from the V3-
loop sequence using bioinformatic tools and algorithms. They are
currently preferred in Europe due to their accessibility, rapid turn-
around and low cost [36,37]. Many prediction tools are available,
with similar specificities and sensitivities despite the fact that they
are based on different algorithms involving the 11/25 rule, the
number of positively charged AA, the overall net charge of the V3
loop, or combinations thereof. Among them, Geno2Pheno[cor-
eceptor] [38] and webPSSM [39] are the most widely used.
European Guidelines for HIV patient management currently
recommend the use of Geno2Pheno[coreceptor] with a 10% false
positive rate (FPR) cut-off, which has been shown to provide the
best balance between specificity and sensitivity for predicting R5
or X4/R5X4 tropism [40–43]. The major caveat of such
algorithms however lies in the fact that they are based on V3-
loop sequences from subtypes B and C mainly, and inadequacies
requiring fine-tuning or subtype-specific rules have been reported
[19,44–46].
This study evaluates the performance of an in-house Env
recombinant viral assay (Env-RVA) targeting the full HIV Env
ectodomain, in comparison to Geno2Pheno[coreceptor] and
webPSSM (Fig. 1). Concordance between the RVA and
Geno2Pheno[coreceptor] with a false positive cutoff set at 10% was
85.2% and concordance with webPSSM was 79.6%. Discordant
results most often involved non-B subtypes, particularly subtype
A1 for webPSSM and CRF01_AE and CRF02_AG for both
algorithms. Repeat experiments in the presence of coreceptor
antagonists and, when possible, testing the sample using the
Trofile ESTA, confirmed phenotypic results of the RVA. Taken
together, these results highlight that prediction algorithms are not
always accurate for predicting tropism of some subtypes,
particularly CRF01_AE and CRF02_AG and underscore the
usefulness of maintaining phenotypic testing as well as to adapt
algorithms for certain subtypes and recombinant forms.
Materials and Methods
Study Population
Plasma samples from 292 patients infected with HIV-1 subtypes
B (73), A1 (17), C (21), D (15), F (15), G (55), CRF01_AE (42) and
CRF02_AG (54) were included in the study. Left-over plasma
obtained from samples for routine clinical tests was used. Ethical
approval for use of left-over plasma was obtained from the Comite´
National d’Ethique pour la Recherche in Luxembourg for HIV
assay validation in Luxembourg for HIV assay validation without
patient informed consent. The IRB waived the need for written
informed consent from the participants for this study. HIV-1
subtypes were determined from HIV-1 PR-RT and Env sequences
spanning the V3-loop using COMET (www.comet.retrovirology.
lu) and the REGA HIV subtyping tool [47]. CD4 counts ranged
from 11 cells/mm3 to 1460 cells/mm3 (mean: 391 and median:
356 cells/mm3). Plasma viral load (VL) (Abbott m2000 RealTime
HIV-1 assay) ranged from 466 to 1,350,000 RNA copies/ml for all
subtypes, with a mean and median of 14,055 and 71,115 RNA
copies/ml respectively. 26/73 subtype B samples with VL ,103
RNA copies/mL were also included to assess the RVA’s
performance for VL ,103 RNA copies/ml.
Cell Culture
HEK293T cells were obtained from ATCC and were main-
tained in DMEM medium supplemented with 10% Fetal Bovine
Serum, 1% Glutamate, 50 mg/ml Penicillin and 50 mg/ml
Streptomycin. U87.CD4.CCR5 and U87.CD4.CXCR4 cells were
obtained from the NIH AIDS Reagent Program and were
maintained in DMEM containing 10% Fetal Bovine Serum, 1%
Glutamate, 300 mg/ml Geneticin and 1 mg/ml Puromycin to
maintain CD4 and co-receptor expression respectively. All media
supplements and antibiotics were sourced from Invitrogen,
Belgium.
Env Amplification
One ml of plasma or of Env-recombinant virus supernatant
was centrifuged at 24,0006g for 1 hour at 4uC and viral RNA
was extracted from the pellet using the Qiagen Viral RNA
extraction kit (Qiagen, Belgium) according to the manufacturer’s
instructions. Viral cDNA was synthesized in a one-step RT-PCR
reaction using forward primer KVL008 and reverse primer
KVL009 [48] in 50 ml mix containing 5 ml viral RNA, 20 mM of
each primer, 1 ml SuperScript III One-Step RT-PCR with
Platinum Taq High Fidelity mix and 8 units RNAseOUT (all
from Invitrogen, Merelbeke, Belgium) under the following
conditions: initial denaturation at 94uC for 2 mins and 40
amplification cycles (94uC for 15 s, 60uC for 30 s, 68uC for 4 mins)
followed by a final 10 mins extension step at 68uC. 2 ml of the
amplified cDNA was further amplified using forward primer MM1
FP (59-GCCTTAGGCATCTCTTATGGCAGGAAGAAG-39)
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and reverse primer rec HR1-2_RP (59-CTCTCTCTfCC-
ACCTTCTTCTTC-39) [27] in a 50 ml reaction mix containing
2 mMMgSO4, 0.2 mM of each dNTP, 20 mM of each primer, 2.5
Units Platinum Taq High Fidelity DNA polymerase. The amplifi-
cation conditions were: initial denaturation step at 95uC for 3 min,
35 cycles of denaturation at 95uC for 30 s, annealing at 48uC for
30 s, extension at 68uC for 3 min, and a final extension step at 68uC
for 10 min. Amplification was verified by agarose gel electropho-
resis. To avoid PCR selection, five independent amplifications were
performed in parallel for each sample and were pooled for
recombinant virus production and sequencing.
Sequencing
To circumvent a potential primer-linked bias, the V3-loop was
sequenced directly from the same Env ectodomain amplicon used
to produce Env-recombinant viruses (Fig. 1). Sequencing was
performed using the BigDye Terminator v3.1 dye on Applied
Biosystems 3500 xL DX genetic analyzer (Applied Biosystems
Europe BV, Belgium), using sense primers 6951 and 6990 and
reverse primers 7336 [49]. For sequencing of viral supernatants,
viral RNA was extracted and amplified as described previously
and a nested PCR was performed using 2 ml of the Env cDNA,
using primers KK1 [50] and DR8 [51] (400 nM each) in a mix
containing 5 ml 106PCR Gold Buffer II, 20 mM dNTPs, 200 mM
MgCl2 and 0.5 ml AmpliTaq Gold DNA polymerase (Applied
Biosystems), in the following cycling conditions: denaturing for
10 mins at 95uC, followed by 40 amplification cycles (15 sec 95uC,
30 sec 55,5uC, 1 min 72uC) and a final 10 mins extension step at
72uC. For those viral supernatants that could not be sequenced
using this method because of inadequate viral content, the viral
RNA was amplified and sequenced using primers KK1 and DR8
(400 nM each) in a one-step RT-PCR reaction containing 10 ml
viral RNA, 1.5 ml of each primer, 10 ml 56buffer, 40 mM dNTPs,
0.1 ml RNAse inhibitor and 2 ml Qiagen Taq (Qiagen), as follows:
RT: 30 mins at 50uC, denaturation: 15 mins 95uC, 40 cycles of
amplification (15 sec 95uC, 30 sec 55.5uC, 1 min 72uC) and a final
5 min extension step at 72uC, followed by an inner PCR using the
same conditions as above. V3-loop sequences are available under
EMBL Nucleotide Sequence Database with accession numbers:
HE972342-HE972511 and JN407569, JN407585, JN407591,
JN407601, JN407602, JN407608, JN407609, JN407611,
JN407624, JN407629, JN407632, JN407661, JN407676,
JN407696, JN407704, JN407706, JN407709, JN407713,
JN407726, JN407738, JN407740, JN407745, JN407747,
JN407805, JN407808, JN407810, JN407813, JN407814,
JN407816, JN407817, JN407836, JN407872, JN407949,
JN407971, JN407987, JN407991, JN408004, JN408005,
JN408022, JN408023, JN408027, JN408043 and JN408058.
Genotyping
The V3 nucleotide sequences were submitted to the Geno2-
Pheno[coreceptor] algorithm (http://coreceptor.bioinf.mpi-inf.mpg.
de) setting the FPR set at 5%, 10%, 15% and 20% and to
webPSSM (http://indra.mullins.microbiol.washington.edu/
PSSM/) using the X4/R5 matrix. The webPSSM subtype C
SINSI matrix was used sor subtype C. When mixtures were
present in the viral population, all possible combinations were
submitted independently to webPSSM and the results were
reported as numbers of R5, X4 or R5/X4 clones for comparison
with the phenotypic assay.
Production of Recombinant Viruses
pNL4.3DEC.Luc has been described elsewhere [27]. Briefly,
pNL4.3DEC.Luc is a NL4-3-derived plasmid deleted of the Env
ectodomain (6225–8314), containing a AfeI restriction site in the
place of Env for linearization and harboring a firefly luciferase gene
in the place of nef. For Env-recombinant viral production, 70%
confluent HEK293T cells were co-transfected with Afe I-
linearized pNL4.3DEC.Luc (Westburg, Netherlands) and pa-
tient-derived Env PCR amplicons using Lipofectamine 2000
(Invitrogen, Merelbeke, Belgium) according to manufacturer’s
instructions. HIV-1 NL4-3 (X4) and NL-AD8 (R5) were used as
positive controls. Cell-free culture supernatants were collected 48
Table 1. Characteristics of phenotypic assays developed for determination of HIV-1 coreceptor usage.
Assay System Env target Producer cells Target cells readout
Detection
limit reference
ESTA Pseudovirions Full Env Hek293T U87.CD4.R5/R4 Luciferase 0.3% X4 [30]
Virco Recombinant viral
particles
gp120 (NH2-V4) Hek293T U87.CD4.R5/R4 eGFP ,10% X4 [32]
Commercial
assays
Phenoscript Recombinant viral
particles
V1–V3 Hek293T U373MG.CD4.R5/X4 b-Galactosidase 5–10% X4 [34]
PhenXR Recombinant viral
particles
V1–V3 HeLa SX22-HeLaR5/X4 b-Galactosidase 1% X4 [71]
Toulouse tropism
test (TTT)
Recombinant viral
particles
Env Ectodomain Hek293T U87.CD4.R5/R4 Luciferase 0.5% X4 [35]
Non-
commercial
assays
Recombinant viral
particles
Full Env Hek293T U87.CD4.R5/R4 or
GHOST.
CD4.R5/X4
Luciferase 1% X4 [72]
Pseudovirions Full Env Hek293T U87.CD4.R5/R4 Luciferase 1% X4 (high
VL)
[33]
5% X4 (low VL)
CRP Env-RVA Recombinant viral
particles
Env ectodomain Hek293T U87.CD4.R5/R4 Luciferase 2.5% X4
5% R5
Abbreviations: ESTA: Enhanced Sensitivity Trofile Assay; Env: Envelope; eGFP: enhanced Green Fluorescent protein; X4: CXCX4-using strains; R5:CCR5-using strains.
doi:10.1371/journal.pone.0060566.t001
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hours post-transfection, clarified by centrifugation and stored at
280uC until use (Fig. 1). Viral production was determined by
quantifying p24 capsid protein using a p24 ELISA test (Perkin
Elmer, Amsterdam, Netherlands). Virus lacking an envelope
produced by transfecting the sole linearized backbone was used
to assess background noise.
Env Recombinant Viral Assay
104 U87.CD4.CCR5 or U87.CD4.CXCR4 cells in 96-well
plates were infected with Env-recombinant viruses (200 pg p24,
quantified by Perkin Elmer kit) by spinoculation at 12006g for 2
hours at 25uC [52], followed by incubation for 1 hour at 37uC.
Medium was replaced and cells were cultured for a further 48
hours, after which luciferase activity was assayed using the
Promega Luciferase assay kit (Promega, Leiden, Netherlands)
according to manufacturer’s instructions. Luminescence readout
was performed on a Tecan microplate reader (Tecan, Switzerland)
over one second exposure. All infections were performed in
triplicate. Recombinant viruses were scored as positive for the
specific coreceptor if the luciferase signal was at least twice the
background.
Where used, 1 mM Maraviroc (CCR5 antagonist) or 1 mM
AMD3100 (CXCR4 antagonist) were added to the cells, the plate
was centrifuged at 4006g for 10 mins at 25uC and incubated at
37uC for 15 mins prior to addition of the recombinant viruses and
spinoculation.
Trofile ESTA
19 samples (5 subtype B, 2 subtype A1, 2 subtype C, 1 subtype
D, 3 CRF01_AE, 6 CRF02_AG) for which phenotypic results
differed from the Geno2Pheno[coreceptor]-inferred results and for
which plasma was available were tested in the TrofileH ESTA.
Statistical Analyses
In this study, we did not assume the RVA nor the genotypic
prediction tools to be the reference test to determine viral tropism,
therefore concordance and Cohen kappa values were assessed
using Statools (www.stattools.net). Concordance between the
Figure 1. Study design/RVA design. Viral RNA was extracted from patient plasma RT-PCR amplified. Env amplicons spanning the Env ectodomain
were further amplified through an inner PCR. Five independent PCRs were pooled to minimize PCR-selection. Recombinant viruses were produced by
co-transfecting HEK293T cells with Afe I-linearized, luciferase-tagged, Env-deleted, viral backbone and patient-derived PCR amplicon. Normalized
amounts of recombinant viruses were used to infect U87.CD4.CCR5 or U87.CD4.CXCR4 indicator cells. Infection was monitored by quantifying
luminescence in the cell lysates. Depending on the outcome of the infection, viruses were classified as either CCR5 tropic, CXCR4 tropic or dual/
mixed. The same patient-derived PCR amplicon used for viral production was sequenced and tropism inferred by Geno2Pheno[coreceptor] and
webPSSM algorithms. The phenotypic and genotypic results were compared. Abbreviations: Env EC: Env ectodomain; gp41-TM-CT: gp41
Transmembrane+cytoplasmic tail.
doi:10.1371/journal.pone.0060566.g001
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phenotypically measured and genotypically predicted tropism was
calculated as follows for each subtype or group of subtypes:
Concordance =Number of samples with the same tropism by both
assays/Total number of samples tested6100. The correlation
between tests is usually considered good when kappa.0.6.
Tropism measured using the RVA was considered to be
concordant with Geno2Pheno[coreceptor] prediction if they both
detected pure R5 or pure X4. When dual/mixed strains were
detected using the RVA, they were considered to be concordant
with an X4 genotypic prediction and discordant with a R5
prediction, as Geno2Pheno only predicts the presence of X4
strains. For comparison with webPSSM, results were considered to
be concordant if both assays provided the same result, i.e. R5, X4,
or Mixed (D/M). D/M samples detected as a purely X4 or purely
R5 sample by the other test were considered to be discordant.
Sensitivity and specificity were calculated using GraphPad Prism
version 5, setting the phenotypic results as ‘true’.
Results
Detection of Minority Variants
To determine the threshold for detecting minority variants,
mixtures containing known proportions of pNLAD8 (R5) and of
pNL4-3 (X4) were PCR-amplified and used to produce R5/X4
mixed Env recombinant viruses. U87.CD4.CCR5 and
U87.CD4.CXCR4 indicator cells were infected with 2-fold serial
dilutions of the recombinant NLAD8:NL4-3 mixtures (20 pg to
12.5 pg). As reported in Fig. 2A, 2.5% NL4-3 (X4) minority
variants could be detected for NL4-3 with signals higher than
200,000 RLU and 5% NL4-3 variants were detectable with pure
NL4-3 signals higher than 50,000 RLU. NLAD8 (R5) minority
variants were detected down to 5% at the highest viral input and
10% for control values above 50,000 RLU (Fig. 2B). In this study,
experiments were included if positive controls (pure NLAD8 and
NL4-3) generated infection signals above 50,000 RLU.
Production of Patient-derived Env-recombinant Viruses
Overall PCR amplification success of patient-derived Envs was
87% (254/292 samples included) (Table 2). Amplification success
was dependent on both subtype and VL. For subtypes A1, B, C,
G, and CRF01_AE and CRF02_AG, amplification was achieved
in 83.3–100% of cases, while for subtypes D and F, amplification
was successful in 66.7% and 46.7% of cases respectively (Table 2).
Of note, for some subtypes (D, F) few samples were available (15)
inflating the relative weight of failed amplification compared to the
overall rate. Both viral load (VL,1,000 RNA copies/mL) and
non-B subtype compromised amplification success: the use of
subtype-specific primers designed to target the most conserved
regions of env and based on the most frequent polymorphisms did
not improve these figures further (data not shown). When stratified
for viral load, amplification succeeded in 94.9% of cases for
VL.100,000 RNA copies/mL, 89.7% of cases for VL between
10,001–100,000 RNA copies/mL, 83.8% of cases for VL between
1,000–10,000 RNA copies/mL and decreased to 70% for
VL,1,000 RNA copies/mL (Fig. 3). Recombinant viruses could
be produced for 231 Envs, as determined by p24 antigen ELISA in
the viral supernatant. Of those, 91.3% were infectious and tropism
was tested (Table 2).
Concordance of Env-RVA with Genotypic Prediction
Tropism determined phenotypically using the Env-RVA was
compared to tropism inferred by the Geno2Pheno[coreceptor] and
webPSSM prediction algorithms based on the V3-loop sequence.
These two algorithms were chosen among all available genotyping
tools because they are the most widely used in the clinic. Results
are reported in Table 2. Overall, concordance between the
phenotypically measured tropism (RVA) and Geno2pheno[corecep-
tor] (10% FPR cutoff) was 85.2% and concordance of the RVA
with webPSSM was 79.5% (Table 2). The overall Cohen kappa
value for comparison with Geno2Pheno was 0.6252, ranging from
0.3226 (CRF01_AE) to 0.9180 (subtype G) (Table 2), reflecting
good concordance of the phenotypic measure with genotypic
prediction. Overall kappa value for comparison of phenotypically
measured tropism with webPSSM was lower (0.4544), ranging
from 0.0745 (CRF02_AG) to 0.6190 (subtype C with webPSSM
subtype C). If detection of the presence of X4 strains is considered
rather than full concordance between the phenotype and the
genotype inferred by webPSSM, then concordance between these
two assays increased to 83.3% (not shown) and Cohen kappa value
reached 0.5240, ranging from 0.1509 (subtype A1) to 0.8262
(subtype G) (Table 2). Among discordant samples, in 14 cases the
outcome of both prediction algorithms was identical but disagreed
with the phenotypic result, while in the remaining cases, the
phenotypically measured tropism disagreed with one algorithm
only (Table 3). Decreasing the Geno2Pheno[coreceptor] FPR cutoff
to 5% (less sensitive to detect X4) increased concordance to
91.4%, as expected, while augmenting the FPR to 15% and 20%
lowered concordance to 81.0% and 79.5% respectively (Table 2).
For all discordant results (FPR cutoff up to 20% for
Geno2Pheno[coreceptor] and webPSSM) for which enough material
was available (50/74 samples) the phenotypic assay was repeated
using CCR5 and CXCR4 inhibitors (1 mM Maraviroc and 1 mM
AMD3100 respectively) (not shown). In all but two cases, the use of
coreceptor inhibitors confirmed tropism. In one case, detection of
X4 minority variants was close to the limit of detection and was
not confirmed in the repeated experiment. In the second case, a
strictly R5 strain by phenotypic measure and webPSSM,
Maraviroc inhibited infection by 3 logs but did not fully inhibit
entry in U87.CD4.CCR5 cells. To rule out the possibility that an
intrinsic bias in the recombination step of the RVA would result in
selection of some strains and in failure to detect some minority X4
strains, we sequenced the V3-loop of Env-recombinant viral
particles used to infect U87 indicator cells. For all re-tested
samples (50), the V3-loop sequence of recombinant viral
supernatants was identical to the V3-loop of the parental PCR
amplicon used to produce the recombinant viruses, and when
submitted to Geno2Pheno[coreceptor], a similar or identical FPR
was obtained (data not shown), strongly arguing against the
hypothesis of a selection due to the recombination process while
generating recombinant viruses. Further, for 18 discordant
samples, tropism was determined using the Trofile ESTA, which
is based on pseudovirions rather than on recombination. Tropism
measured using the Trofile ESTA confirmed the RVA results in
16/18 positive tests (Table 3). In one case (CRF01_AE) the RVA
failed to detect a minority X4 strain, reflecting the low infectivity
of this recombinant, whereas in the second case (CRF02_AG), the
RVA detected the presence of low X4 variants which were
undetectable using the Trofile ESTA, potentially a consequence of
PCR selection due to the sample’s plasma viral load being near the
limit validated for the assay.
Characterization of Discordant Outcomes
Most discordant cases involved non-B subtypes for Geno2Phe-
no[coreceptor] (10%FPR) (5.6% discordant cases for subtype B,
Cohen kappa= 0.8591, versus 17.9% for non-B subtypes, Cohen
kappa= 0.5446), but not for webPSSM, for which 20.4% (Cohen
kappa= 0.3926) and 20.5% (Cohen kappa= 0.4734) discordant
cases were recorded for subtype B and for non-B subtypes
Genotyping Tools Overestimate CXCR4-Usage for CRFs
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Figure 2. Detection of minority CXCR4 and CCR5 using variants within mixed viral populations. Mixtures containing known proportions
of pNLAD8 and pNL4-3 (100:0, i.e. pure NLAD8, 99:1, 97.5:2.5, 95:5, 90:10, 80:20, 50:50, 20:80, 10:90, 5:95, 2.5:97.5, 1:99, 0:100, i.e. pure NL4-3) were
PCR-amplified and used to generate recombinant viruses. U87.CD4.CCR5 and U87.CD4.CXCR4 indicator cells were infected with serial 2-fold dilutions
(x-axis) of mixtures (z-axis) to determine the threshold for detection of minority variants. Infection was quantified 48 hours after infection by
measuring luciferase activity in cell lysates (y-axis). Black bars report infection of U87.CD4.CXCR4 cells and grey bars report infection of U87.CD4.CCR5
cells. Panels A and B report the same data, oriented to focus on NL4-3 minority variants (A) or on NLAD8 minority variants (B).
doi:10.1371/journal.pone.0060566.g002
Genotyping Tools Overestimate CXCR4-Usage for CRFs
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e60566
respectively (Table 2, Fig. 4). For Geno2Pheno[coreceptor], the
highest kappa values were recorded for subtypes G and B, and the
lowest value for CRF01_AE. For webPSSM, good kappa values
were recorded for subtypes C (using the webPSSM subtype C
matrix); using the subtype B X4/R5 matrix, good kappa values
were also seen for subtypes D, G, F and CRF01_AE, intermediate
for subtypes B, and poor for subtypes A1 and CRF02_AG
(Table 2). Of note, kappa values increased to 0.4752 for subtype B
when detection of X4 strains was compared rather than absolute
concordance (i.e. D/M and D/M, X4 and X4), probably
reflecting tuning of the algorithm for the detection of X4 strains.
The sensitivity and specificity of Geno2Pheno[coreceptor] and
PSSM with respect to the recombinant viral assay (setting the
phenotypic measure as ‘true’) was calculated: overall sensitivity
and specificity were 88.9% and 84.2% for Geno2Pheno[coreceptor]
(10% FPR cutoff) and 65.2% and 88.4% for webPSSM
(considering the ability to detect the presence of X4 variants)
(data not shown). For subtype B strains, sensitivity and specificity
were 100% and 92.7% respectively for Geno2Pheno[coreceptor]; for
webPSSM, sensitivity and sensitivity were 46.1% and 95.1%
respectively (data not shown). For non-B subtypes, sensitivity was
84.4% for Geno2Pheno[coreceptor] and 72.7% for webPSSM (data
not shown). Specificities ranged from 50% to 100% for
Geno2Pheno[coreceptor] and from 50 to 100% for webPSSM (data
not shown), in line with previous reports [53–57].
For subtype B samples, Geno2Pheno[coreceptor] overestimated
X4 usage for all 3 discordant samples. In contrast, webPSSM
failed to detect CXCR4 usage for 7/11 samples (Table 3). Neither
viral load nor the presence of mixtures could account for failure to
detect X4 minor strains. For non-B subtypes, Geno2Pheno[cor-
eceptor] predicted CXCR4 usage while the phenotypic assay
identified strictly R5 strains in most cases, and particularly for
CRF01_AE (12/14 cases) and CRF02_AG (6/7) (Table 3). Such
skewing towards overestimating the presence of X4 minority
variants for these CRFs was maintained when the FPR cut-off was
shifted, although these observations did not reach statistical
significance using a Fisher’s exact test (p,0.05). Disagreement of
the phenotypically measured tropism with webPSSM was
observed chiefly for subtype A1 (40% disagreement) and
CRF01_AE (28.2% disagreement). For CRF01_AE, webPSSM
predicted CXCR4 usage while the phenotypic RVA reported
strictly R5 strains in 7/11 cases, and in 2/11 cases, CXCR4 usage
detected phenotypically was missed by webPSSM (Table 3). For
Figure 3. Distribution of PCR amplification success stratified by
viral load. The Env ectodomain was amplified from plasma viral RNA
by a one-step RT-PCR followed by an inner PCR. Five independent PCR
amplifications were pooled to minimize primer-related selection. 292
samples from patients infected with HIV subtypes A1, B, C, D, F, G,
CRF01_AE and CRF02_AG were included. Viral load ranged from 466 to
1,350,000 RNA copies/mL.
doi:10.1371/journal.pone.0060566.g003
Table 2. Distribution of samples, phenotyping and genotyping, and concordance between phenotypic and genotypic tropism.
Samples Env PCR RVA result
V3 loop
sequence
Pheno/
geno
paired
results Concordance of RVA with Cohen kappa values
Subtype N N % N % N %
G2P:
5%
G2P:
10%
G2P:
15%
G2P:
20% PSSM
G2P:
10% PSSM
PSSM
X4
A1 17 17 100.0% 17 100.0% 15 88.2% 15 93.3% 86.7% 73.3% 73.3% 60.0% 0.4444 0.1743 0.1509
B 73 62 84.9% 62 100.0% 54 87.1% 54 100.0% 94.4% 90.7% 88.9% 79.6% 0.8591 0.3926 0.4752
C 21 21 100.0% 21 100.0% 20 95.2% 20 90.0% 90.0% 85.0% 80.0% 90.0%* 0.6078 0.6190* 0.6078*
D 15 10 66.7% 10 100.0% 7 70.0% 7 85.7% 71.4% 71.4% 71.4% 85.7% 0.3636 0.6111 0.5882
F 15 7 46.7% 7 100.0% 6 85.7% 6 83.3% 83.3% 83.3% 66.7% 83.3% 0.5714 0.5714 0.5714
G 55 52 94.5% 44 84.6% 42 80.8% 40 100.0% 97.5% 95.0% 95.0% 87.5% 0.9180 0.5910 0.8268
CRF01_AE 42 40 95.2% 39 97.5% 40 100.0% 39 79.5% 64.1% 61.5% 61.5% 71.8% 0.3226 0.5153 0.5351
CRF02_AG 54 45 83.3% 32 71.1% 30 66.7% 29 82.8% 79.3% 72.4% 72.4% 79.3% 0.4494 0.0745 0.2077
All non-B 219 192 87.7% 170 88.5% 160 83.3% 156 88.5% 82.1% 77.6% 76.3% 79.5% 0.5446 0.4734 0.5411
Total 292 254 87.0% 232 91.3% 214 84.3% 210 91.4% 85.2% 81.0% 79.5% 79.5% 0.6252 0.4544 0.5240
Distribution of samples per subtype, successful Env PCR amplification, recombinant virus production and sequencing of the V3-loop, and results (concordance and
Cohen kappa values) for genotype/phenotype pairs are reported.
N: number of samples. G2P: Geno2Pheno(coreceptor). The percentage following G2P indicates the FPR cut-off. Distribution of samples per subtype, successful Env PCR
amplification, recombinant virus production and sequencing of the V3-loop, and results (concordance and Cohen kappa values) for genotype/phenotype pairs are
reported.
*For subtype C, concordance was determined and with webPSSM subtype C SINSI. Concordance with webPSSM X4/R5 was 75% and Cohen kappa values were poor
(20.0989 for full agreement and 20.1365 when detection of X4 strains was considered).
doi:10.1371/journal.pone.0060566.t002
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Table 3. Detail of discordant results between RVA, ESTA, Geno2Pheno(coreceptor) and webPSSM.
HIV-1 subtype RVA result
Trofile
result G2P webPSSM Discordance
5% cutoff 10% cutoff 15%cutoff 20% cutoff FPR G2P PSSM
A1 R5 R5 R5 X4 X4 X4 6.8 X4 G2P 10% PSSM
A1 R5 N/A R5 X4 X4 X4 8.5 D/M G2P 10% PSSM
A1 R5 R5 R5 R5 X4 X4 10.5 X4 G2P 15% PSSM
A1 R5 N/A R5 R5 R5 R5 42.2 D/M agree PSSM
A1 R5 N/A R5 R5 R5 R5 40.3 X4 agree PSSM
A1 R5 N/A R5 R5 R5 R5 22.6 D/M agree PSSM
B R5 R5 R5 X4 X4 X4 6.7 R5 G2P 10% agree
B R5 failed R5 X4 X4 X4 6.8 R5 G2P 10% agree
B R5 N/A R5 R5 X4 X4 13.8 R5 G2P 15% agree
B R5 N/A R5 R5 X4 X4 10.5 R5 G2P 15% agree
B R5 N/A R5 R5 R5 X4 17.6 R5 G2P 20% agree
B R5 R5 R5 X4 X4 X4 6.9 R5 G2P 10% agree
B D/M D/M X4 X4 X4 X4 4.6 R5 agree PSSM
B R5 N/A R5 R5 R5 R5 26.2 D/M agree PSSM
B X4 N/A X4 X4 X4 X4 0.7 D/M agree PSSM partial
B R5 N/A R5 R5 R5 R5 72.8 D/M agree PSSM
B X4 N/A X4 X4 X4 X4 3.7 R5 agree PSSM
B X4 N/A X4 X4 X4 X4 3.8 D/M agree PSSM partial
B X4 N/A X4 X4 X4 X4 4.7 R5 agree PSSM
B X4 N/A X4 X4 X4 X4 3.8 R5 agree PSSM
B X4 N/A X4 X4 X4 X4 3.7 R5 agree PSSM
B X4 N/A X4 X4 X4 X4 3.8 R5 agree PSSM
B X4 N/A X4 X4 X4 X4 3.8 R5 agree PSSM
C D/M N/A R5 X4 X4 X4 6.9 R5 G2P 5% agree
C R5 R5 R5 X4 X4 X4 9.6 R5 G2P 10% agree
C R5 N/A R5 R5 X4 X4 10.9 X4 G2P 15% PSSM
C R5 N/A R5 R5 R5 X4 17.9 R5 G2P 20% agree
C D/M N/A R5 R5 R5 R5 28.8 R5 G2P 5% PSSM
D R5 R5 X4 X4 X4 X4 4.7 X4 G2P 5% PSSM
D R5 R5 R5 X4 X4 X4 6.8 R5 G2P 10% agree
G R5 N/A R5 X4 X4 X4 5 R5 G2P 10% agree
G R5 N/A R5 R5 X4 X4 13.2 R5 G2P 15% agree
G D/M N/A R5 X4 X4 X4 6.8 R5 G2P 5% PSSM
G D/M N/A X4 X4 X4 X4 1.3 X4 agree PSSM partial
G D/M N/A X4 X4 X4 X4 1.7 X4 agree PSSM partial
G D/M N/A X4 X4 X4 X4 1.1 X4 agree PSSM partial
G R5 N/A R5 R5 R5 R5 26.9 D/M agree PSSM
F D/M N/A R5 X4 X4 X4 6.9 D/M G2P 5% agree
F R5 N/A R5 R5 X4 X4 14.4 R5 G2P 15% agree
F R5 N/A R5 R5 R5 X4 17.5 R5 G2P 20% agree
F D/M N/A X4 X4 X4 X4 1.7 R5 agree PSSM
AE R5 R5 R5 X4 X4 X4 5.3 R5 G2P 10% agree
AE R5 N/A R5 X4 X4 X4 7.9 D/M G2P 10% PSSM
AE R5 N/A X4 X4 X4 X4 1.8 X4 G2P 5% PSSM
AE R5 N/A X4 X4 X4 X4 2.7 D/M G2P 5% PSSM
AE R5 D/M X4 X4 X4 X4 1.8 X4 G2P 5% PSSM
AE D/M N/A X4 X4 X4 X4 1.7 X4 agree PSSM partial
AE R5 N/A R5 X4 X4 X4 9.6 R5 G2P 10% agree
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Table 3. Cont.
HIV-1 subtype RVA result
Trofile
result G2P webPSSM Discordance
5% cutoff 10% cutoff 15%cutoff 20% cutoff FPR G2P PSSM
AE R5 N/A R5 X4 X4 X4 5.7 R5 G2P 10% agree
AE R5 N/A R5 X4 X4 X4 5.7 R5 G2P 10% agree
AE D/M N/A R5 X4 X4 X4 8.7 D/M G2P 10% agree
AE R5 N/A R5 X4 X4 X4 5 D/M G2P 10% PSSM
AE R5 N/A R5 R5 X4 X4 10.5 R5 G2P 15% agree
AE R5 N/A R5 R5 X4 X4 10.5 R5 G2P 15% agree
AE R5 N/A R5 R5 X4 X4 12 R5 G2P 15% agree
AE R5 N/A X4 X4 X4 X4 4.1 D/M G2P 5% PSSM
AE D/M N/A R5 R5 R5 R5 77.2 R5 G2P 5% PSSM
AE R5 N/A X4 X4 X4 X4 4.7 X4 G2P 5% PSSM
AE D/M N/A R5 R5 X4 X4 10.5 R5 G2P 5–10% PSSM
AE D/M N/A X4 X4 X4 X4 1.7 X4 agree PSSM partial
AG R5 R5 R5 X4 X4 X4 6.4 R5 G2P 10% agree
AG R5 R5 R5 X4 X4 X4 9.6 R5 G2P 10% agree
AG R5 N/A R5 R5 X4 X4 13.8 R5 G2P 15% agree
AG R5 R5 R5 R5 X4 X4 10.2 R5 G2P 15% agree
AG R5 R5 X4 X4 X4 X4 4.8 R5 G2P 5% agree
AG R5 N/A X4 X4 X4 X4 2.6 R5 G2P 5% agree
AG R5 N/A R5 X4 X4 X4 6.8 R5 G2P 10% agree
AG D/M R5 R5 R5 R5 R5 40.7 R5 G2P 5% PSSM
AG D/M N/A R5 X4 X4 X4 5.8 R5 G2P 5% PSSM
AG/G R5 R5 R5 R5 X4 X4 10.1 R5 G2P 15% agree
AG D/M N/A X4 X4 X4 X4 1.7 R5 agree PSSM
AG D/M N/A X4 X4 X4 X4 0.5 X4 agree PSSM partial
AG R5 N/A R5 R5 R5 R5 39.6 D/M agree PSSM
AG D/M N/A X4 X4 X4 X4 5.3 R5 agree PSSM
G2P: Geno2Pheno; FPR: False Positive Rate; D/M: dual mixed N/A= sample was not analyzed; PSSM ‘partial’ refers to samples for which webPSSM agrees with the
phenotypic result for the detection of X4 variants, but not on the presence or absence of CCR5-using variants.
doi:10.1371/journal.pone.0060566.t003
Figure 4. Concordance between tropism measured phenotypically and inferred genotypically using the Geno2pheno(coreceptor) and
webPSSM algorithms. (A) Concordance for subtype B (black bars) and non-B subtype (grey bars) strains with Geno2Pheno (G2P) at different FPR
cutoffs and webPSSM. (B) Concordance with Geno2pheno(coreceptor) with a FPR set at 10% (black bars) and webPSSM (grey bars) for different HIV-1
subtypes. The webPSSM X4/R5 matrix was used for all subtypes, except for subtype C, for which the subtype C SI/NSI matrix was used.
doi:10.1371/journal.pone.0060566.g004
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subtype A1, CXCR4 usage was overestimated in all cases (6/6
discordant cases) (Table 3).
Overall, both Geno2Pheno[coreceptor] and webPSSM overesti-
mate the presence of X4 viruses for CRF01_AE. A similar trend
was also observed for Geno2Pheno[coreceptor] in the case of
CRF02_AG and for webPSSM in the case of subtype A1,while
webPSSM underestimates the presence of X4 for subtype B.
Taken together, these results point to an inadequacy of the
genotypic prediction algorithms in correctly inferring tropism for
some subtypes CRF01_AE and CRF02_AG, and for subtype A1
in the case of webPSSM.
Discussion
In this study, the performance of an in-house Env-recombinant
viral assay for determining viral tropism was evaluated in
comparison to genotypic prediction using 2 widely used algo-
rithms, Geno2Pheno[coreceptor] [38] and webPSSM [39] on a
majority of non-B subtypes. Overall, we found good concordance
between our phenotypic assay and these algorithms, as reflected by
85.2% concordance of the phenotype with Geno2Pheno[coreceptor]
and 79.5% with webPSSM and relative kappa values of 0.6252
and 0.4544 respectively. The highest genotypic/phenotypic
concordance was generally found for subtypes G, B and C strains,
whereas, despite improved rules, substantial discordances involved
non-B subtypes and CRFs. This is in line with previous studies
reporting the performance of genotypic tools, mainly webPSSM
(X4/R5 and SINSI matrices), Wetcat, Geno2Pheno[coreceptor] or
the 11/25 rule, compared to the Phenoscript test or to the Trofile
phenotypic assay [53,58,59] measuring the sensitivity and
specificity of these algorithms to detect the presence of X4 strains.
In order to compare our findings with previous reports which
evaluated the reliability of different genotypic prediction tools for
detecting X4 strains, sensitivity and specificity of these algorithms
with respect to the recombinant viral assay were calculated,
although this approach presents the intrinsic drawback of setting
the phenotypic assay as the standard. We found overall good
sensitivities with Geno2Pheno and webPSSM, similar to previous
reports on the sensitivity and specificity ranges of different
bioinformatics tools for subtype B and some non-B strains [53–
58]. Of note however, despite similar conclusions, concordance of
different genotypic prediction tools with phenotypic assays did not
always agree on which algorithm performed best, probably
reflecting differences in the panel of viruses and of subtypes
included, primer selection, and subsequent comparison with
different phenotypic assays targeting the full Env or just the V1–
V3 portion. Although the purpose of this study was not to compare
the performance of different bioinformatics tools for detecting X4
minority variants but rather to validate our in-house RVA, our
findings confirm the high reliability of genotypic prediction tools
for detecting the tropism of subtype B strains [53,54,56], but also
highlight incongruent results for many non-B strains. This has
been addressed by webPSSM by developing a specific matrix for
subtype C. Concordance of webPSSM with phenotypic results
increased from 75% using the webPSSM X4/R5 matrix (based on
subtype B) (data not shown) to 90% using the webPSSM subtype C
matrix; likewise Cohen kappa values shifted from negative (data
not shown) to .0.6 using both algorithms respectively. Therefore,
it is important to consider subtype when assessing the presence of
X4 strains in the clinical context prior to maraviroc prescription.
Our findings strongly argue in favor of using multiple genotypic
prediction tools and to consider maintaining phenotypic testing for
those subtypes for which coreceptor usage determination using
genotypic tests features low concordance with phenotypic mea-
sures, and for which prediction algorithms have not been tuned
specifically, i.e. non-B, and non-C subtypes.
In this study, genotypic prediction featured the highest
discordance with CRF01_AE and CRF02_AG and subtype A1.
Of note, Geno2Pheno[coreceptor] and webPSSM did not always
predict the same tropism, as previously reported [60]. Geno2Phe-
no[coreceptor] tended to overestimate the presence of CXCR4 usage
(Table 3), while WebPSSM overestimated CXCR4-usage for
subtype A1, but not for subtype B or CRF01_AE and CRF02_AG
(Table 3). It may be important to keep in mind that when mixtures
are present in the V3-loop, all possible combinations are
genotyped, and the algorithm provides a tropism prediction for
each possible clone. In this scenario, webPSSM would infer
tropism for sequences that do not exist in the viral population,
eventually leading to an overestimation of dual tropic variants,
whereas the phenotypic assays only measures existing strains.
Although this phenomenon does not account for mistakenly
assigned coreceptor usage, (e.g. strict X4 rather than strict R5), it
could explain the improved kappa values recorded for some
subtypes when the reliability in detecting the presence of CXCR4-
using variants is compared. Such an improvement was particularly
marked for subtypes B, G and CRF02_AG (Table 2).
Poor specificity has previously been reported for tropism
prediction of subtype D strains by Geno2Pheno[coreceptor] [46]
and for CRF02_AG [19,45], for which specific determinants have
been described to improve the algorithm. We therefore subjected
our samples to the rules provided by Raymond [45] and those
proposed shortly after by Esbjo¨rnsson [19] for CRF02_AG: the
Raymond rules, which combine the 11/25 rule and the net charge
rule (R/K at position 11 and/or K at position 25, or R at position
25+ net charge $+5 or the net charge $+6) [45,61] resulted in 7
discordant cases (20.7%) (3 R5 samples scored as X4 and 3 X4
samples scored as R5) and the Esbjo¨rnsson rule (net charge $ +5
and total charged AA $8) [19] in 10 discordances (34.5%) (4
missed X4 calls and 6 X4 calls for R5 viruses). Therefore, the
Raymond rules slightly improved concordance of genotypic
prediction with phenotypic measure for CRF02_AG compared
to Geno2Pheno[coreceptor] and webPSSM while the Esbjornsson
rules further increased false positive X4 calls on our samples.
While this manuscript was under revision, Raymond et al.
reported similarly low sensitivity and specificity of Geno2Pheno[-
coreceptor] (10% FPR cutoff) for CRF01_AE, and proposed a new
rule combining the 11/25 rule and disruption of the potential N-
glycosylation site PNG (N6NT8) within the V3-loop [62]. Using a
similar approach, we found that in our samples, the presence of a
positively charged AA (K or R) at positions 11 or 25 was relatively
rare (R/K at position 11 in 6/40 sequences and K at position 25
in one sequence), but reliably translated into CXCR4 usage
measured phenotypically. Position 11 hosted a S in 30/40
sequences and a G in 3/40 sequences; position 25 displayed a
negatively charged AA (D or E) in 35 sequences. The total number
of positively charged AA, total net charge, or total charge, which
was generally high (.+5), did not provide further support for
sorting CXCR4-using strains in our samples, in agreement with
the findings reported by Raymond et al. [62]. In 6/8 phenotyp-
ically X4 strains in which positions 11 and 25 were not positively
charged, the PNG (N6NT8) was (or was likely to be, due to
mixtures) disrupted and the net charge was $+4, as reported by
Raymond et al. [62]. The Raymond rules improved concordance
of the phenotypic test with genotypic prediction from 61.4% with
Geno2Pheno[coreceptor] and 71.8% with webPSSM to 87.2% (34/
39) for this CRF. Nonetheless, with these rules (11 K/R and/or
25 K or disrupted PNG+net charge$+4 [62]) in 2/25 cases,
phenotypically R5 samples were scored as X4 and 2/14
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phenotypically X4 samples were predicted to be R5, suggesting
that other criteria apply to this CRF and larger scale studies
combining phenotypic testing to genotypic tuning combining the
11/25 rule to the PNG and to charge will be needed to further
improve sensitivity and specificity of prediction tools. We cannot
exclude that in our study, the use of bulk sequences may impact
the reliability of prediction rules, whereas the rules by Raymond
were partially based on clonal samples, where the relative weight
of each position is absolute rather than being relative to its
proportion within the quasispecies.
Three technical reasons could account for discordant results
between genotypic prediction and phenotypically determined
tropism: PCR selection, a bias/selection arising from the
recombination step of the RVA, inadequately inferred tropism
by genotypic tools, consequent to subtype-related specificities not
taken into account by the algorithm, either within the V3 loop or
in other regions of Env. To minimize a potential impact of PCR
selection, 5 independent PCR reactions were pooled and the same
amplicon used to produce recombinant viruses was sequenced.
Nonetheless, whereas comparison of the Env-RVA and genotypic
prediction by Geno2Pheno and webPSSM were based on the use
of the same PCR pool, the Trofile ESTA was performed using an
independent plasma tube and different PCR primers, eventually
translating into PCR selection. Hence, it is not possible to exclude
that failure to pick-up X4 minority variants by the RVA (1
CRF01_AE) or by the Trofile ESTA (1 CRF02_AG), reflect PCR
selection, particularly in the case of poorly infectious recombinant
or pseudotyped particles. Selection during the recombination step
was ruled out as the V3-loop sequences from viral supernatants
(after the recombination step) were identical to the parental PCR
amplicon that served to produce recombinant viruses. When
assessed, tropism of CRF01_AE and CRF02_AG strains assessed
using the Trofile ESTA matched the phenotype determined by the
RVA and disagreed with the Geno2Pheno[coreceptor] prediction in
all but two cases (Table 3). The Trofile ESTA was chosen among
all available tropism phenotypic tests because it is a high sensitivity
and specificity single cycle pseudovirus assay [30]. Lastly, repeat
experiments in the presence of CCR5 and CXCR4 inhibitors
confirmed the phenotypic results, strongly indicating that the
Geno2Pheno[coreceptor] and webPSSM algorithms require more
specific improvements for some subtypes, particularly CRF01_AE
and CRF02_AG, and that the RVA described here reliably
indicates coreceptor usage. It is known that the V3-loop is not the
sole Env determinant of HIV-1 co-receptor usage. Sequence
changes within the V1, V2 and C4 regions of gp120 [13,63–67], as
well as the level of glycosylation [68–70] can also profoundly
impact coreceptor usage. In this study, it is not possible to rule out
that some discordant results arise from the comparison of
coreceptor usage predictions based on the V3-loop sequence only
to a phenotypic assay taking into account the whole Env
ectodomain.
Various commercial and non-commercial phenotypic assays
have been developed over the last 10 years to measure tropism.
These are based on different approaches to produce recombinant
viruses, including homologous recombination, pseudotyping, or a
combination of both; they target different parts of Env, ranging
from the V1–V3 region only (e.g. Phenoscript [34], PhenXR [71])
to the full Env (e.g. ESTA [30]); the producer and the target cells,
as well as the readout (virally-encoded luciferase or GFP reporter
gene (e.g. ESTA [30], TTT [35], the Virco Assay [32], two non-
commercial assays utilizing recombinant particles and pseudovir-
ions respectively [33,72], and the RVA presented here), or target
cell line containing a LTR-b-Galactosidase reporter which is
activated upon infection (e.g. Phenoscript [34], PhenXR [71])
further distinguish these tests. These are recorded in Table 1. The
RVA presented here mostly resembles the TTT assay in the design
of the backbone, production of recombinant viral particles through
homologous recombination and location of Luciferase reporter in
the place of Nef [35]. The TTT showed high performance in
terms of Env amplification and production of recombinant viruses,
particularly for subtypes that were difficult to amplify using our
primers (D and F), likely due to primer location. The TTT group
also selected one U87-CD4.CXCR4 cell clone with high
expression of CXCR4 to increase the limit of detection of X4
minority variants [35]. In our design, we verified the expression of
CXCR4 and only maintained cells in culture for a limited number
of passages. To ensure the lower limit of detection of X4 strains
was maintained, we tested the performance of the RVA using
serial dilutions and systematically discarded experiments where the
lower threshold of infection of U87.CD4.CXCR4 cells by NL4-3
did not reach 100,000 RLU (Fig. 2). It would be interesting to
compare the performance of different phenotypic assays using a
large panel of samples, although this could not be performed here
because of insufficient plasma from the sample to allow
independent testing and repeat experiments in different laborato-
ries.
Taken together, the findings reported here strongly support the
need for further large-scale studies to improve prediction models
and/or to appeal to more than one algorithm when non-B
subtypes are involved. The use of phenotypic measurements could
nevertheless be required in cases where different algorithms point
to potential difficulties in inferring the correct tropism. Such a
confirmation is important in the clinical set-up as a false prediction
of X4 variants may lead to exclusion of patients who could have
benefited from prescription of CCR5 inhibitors while false
prediction of R5 only variants may lead to selection and
reemergence of X4-strains under maraviroc pressure (Baatz et al.,
2011; Kuhmann and Hartley, 2008; Pugach et al., 2007; Westby
et al., 2007).
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